Review Article on Quality by Design in Pharmaceutics: Enhancing Drug Development and Manufacturing

Quality by Design (QbD) is a proactive, systematic approach in the pharmaceutical industry that ensures the consistent quality and safety of drug products. It emphasizes understanding and controlling critical quality attributes (CQAs) and their relationship with process parameters during the drug development and manufacturing phases. This article explores the evolution of QbD, its historical context, and the perspective of regulatory bodies like the FDA. It also highlights the current applications of QbD in the pharmaceutical industry, with a focus on how it addresses product quality and regulatory compliance. Furthermore, the article discusses the challenges pharmaceutical companies face in adopting QbD, such as resource constraints and the complexity of implementation. The article also examines the benefits of QbD, such as improved product consistency and reduced regulatory hurdles, alongside its limitations, including the need for substantial upfront investment and expert knowledge. Finally, it provides insights into how QbD is shaping the future of pharmaceutical manufacturing and regulatory approaches, positioning it as an essential framework for achieving high-quality drug products.

Publication Details

Journal
Zenodo (CERN European Organization for Nuclear Research)
Published
2025-03-07
DOI
https://doi.org/10.5281/zenodo.14989853
Primary Topic
Pharmaceutical Quality and Counterfeiting
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Review Article on Quality by Design in Pharmaceutics: Enhancing Drug Development and Manufacturing

Zenodo (CERN European Organization for Nuclear Research)
Pharmaceutical Quality and Counterfeiting
article

Review Article on Quality by Design in Pharmaceutics: Enhancing Drug Development and Manufacturing

article en

Abstract

Quality by Design (QbD) is a proactive, systematic approach in the pharmaceutical industry that ensures the consistent quality and safety of drug products. It emphasizes understanding and controlling critical quality attributes (CQAs) and their relationship with process parameters during the drug development and manufacturing phases. This article explores the evolution of QbD, its historical context, and the perspective of regulatory bodies like the FDA. It also highlights the current applications of QbD in the pharmaceutical industry, with a focus on how it addresses product quality and regulatory compliance. Furthermore, the article discusses the challenges pharmaceutical companies face in adopting QbD, such as resource constraints and the complexity of implementation. The article also examines the benefits of QbD, such as improved product consistency and reduced regulatory hurdles, alongside its limitations, including the need for substantial upfront investment and expert knowledge. Finally, it provides insights into how QbD is shaping the future of pharmaceutical manufacturing and regulatory approaches, positioning it as an essential framework for achieving high-quality drug products.

Zenodo (CERN European Organization for Nuclear Research)
Industry, innovation and infrastructure
Openalex Percentile: Top 47%
Pharmaceutical Quality and Counterfeiting
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Review Article on Quality by Design in Pharmaceutics: Enhancing Drug Development and Manufacturing · Zenodo (CERN European Organization for Nuclear Research) (2025) | TGRS Research Map | TGRS